Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Dennis C who wrote (108)	1/13/1999 1:57:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

Dennis: Glad that you responded. My post was bit provocative, in hope that someone will bait. When I picked NBIX (with few other in CNS field) in 98, it was based on their technology and view that chemistry is integral part of their business. Company which are dealing with CNS disorder have to have good chemistry and large small molecules libraries. <<. Recently they hired a new VP who had worked for CombiChem. >> Did I miss something? Or you had in mind J. A. Mollicia (PCOP CEO) who was recently elected as Board Cherman? <<Do you have idea about the average cost/compound/screening? >> No, no idea. I am old generation chemist, do it yourself, compound by compound. The point is to share R&D cost with other bt company, reduced cash burn, and later if collaboration do generate drug development program and candidate, license it and shared profit, if drug is approved. Very simple. It should work! :) Miljenko